Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with spinal cord involvement Studies in large animal
AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the appointment
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia Intrathalamic
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.